By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to accelerating the development of safe and effective treatments for pediatric cancer, has officially announced the appointment of Mark Zafra to its Board of Directors. Zafra, a highly regarded executive with more than two decades of experience in global supply chain management and procurement, currently serves as the Chief Procurement Officer at LiveRamp. His appointment comes at a critical juncture for the organization as it seeks to bridge the gap between laboratory research and clinical application through strategic leadership and operational excellence.
The inclusion of Zafra on the board is viewed by industry analysts and non-profit advocates as a strategic move to integrate high-level corporate efficiency into the philanthropic sector. Zafra’s extensive background in sourcing and procurement for some of the world’s most influential technology and healthcare companies provides CureSearch with a unique perspective on resource allocation and strategic scaling. Beyond his professional accolades, Zafra brings the invaluable perspective of a cancer survivor, marking 2024 as the 20th anniversary of his initial diagnosis—a milestone he intends to commemorate through both governance and physical endurance.
Professional Trajectory and Strategic Expertise
Mark Zafra’s career is defined by a consistent record of leading large-scale transformation initiatives within complex global organizations. As the Chief Procurement Officer at LiveRamp, a prominent data collaboration platform, Zafra is responsible for the oversight of global strategic sourcing, purchasing, travel, and accounts payable. His role is central to the company’s operational health, ensuring that resources are utilized effectively to drive innovation and maintain a competitive edge in the fast-paced technology sector.
Prior to his tenure at LiveRamp, Zafra held senior leadership positions at several Fortune 500 companies and industry disruptors. At Twitter, he managed global procurement strategies during a period of significant platform growth and infrastructure expansion. His experience also spans the healthcare and technology sectors with notable stints at McKesson, one of the largest healthcare companies in the world, as well as Hewlett-Packard (HP) and Agilent Technologies. Additionally, his work with Allianz Fireman’s Fund provided him with deep insights into the insurance and risk management industries.
This diverse portfolio of experience is particularly relevant to CureSearch’s mission. The process of bringing a new pediatric cancer drug to market is fraught with logistical hurdles, regulatory complexities, and the need for efficient resource management. Zafra’s expertise in supply chain optimization and strategic sourcing is expected to assist the board in navigating the "valley of death"—the precarious gap between early-stage research and the successful commercialization of life-saving therapies.
A Personal Mission: From Survivor to Advocate
While Zafra’s professional resume is formidable, it is his personal history that provides the emotional and ethical foundation for his board service. Exactly twenty years ago, Zafra received a cancer diagnosis that fundamentally altered his life path. Having successfully navigated the rigors of treatment and long-term recovery, he has transitioned from a patient to a passionate advocate for the oncology community.
His commitment to the cause is not limited to the boardroom. Later this year, Zafra will participate in the CureSearch Ultimate Hike in Jackson, Wyoming. The Ultimate Hike is a signature fundraising program for the organization, challenging participants to complete a rigorous 20-plus mile trek in a single day through demanding terrain. The event serves a dual purpose: it raises critical funds for cutting-edge childhood cancer research and honors those who have battled the disease. For Zafra, the Jackson, WY hike is a poignant way to mark two decades of survivorship while actively contributing to the future of pediatric oncology.
The State of Childhood Cancer Research and Funding
To understand the significance of Zafra’s appointment, it is necessary to examine the current landscape of childhood cancer research in the United States. According to data from the National Cancer Institute (NCI), more than 15,000 children and adolescents under the age of 20 are diagnosed with cancer each year. While survival rates have improved significantly since the mid-20th century, cancer remains the leading cause of death by disease among children in the U.S.
One of the primary challenges facing the field is the disparity in research funding. Historically, only about 4% of the federal budget for cancer research is allocated specifically to pediatric cancers. This necessitates a heavy reliance on private philanthropy and organizations like CureSearch to drive innovation. Furthermore, because pediatric cancers are considered "orphan diseases" due to their relatively small patient populations compared to adult cancers, pharmaceutical companies often face fewer economic incentives to develop new pediatric-specific drugs.
CureSearch addresses this gap by focusing on "high-potential" research that is most likely to reach clinical trials. By utilizing a venture-philanthropy model, the organization ensures that every dollar invested is geared toward accelerating the pace of drug development. The addition of a procurement expert like Zafra is a logical extension of this efficiency-first approach.
Chronology of Mark Zafra’s Integration into CureSearch Leadership
The path to Zafra’s appointment involves a series of strategic engagements and a long-standing alignment with the organization’s core values:
- 2004: Mark Zafra receives his initial cancer diagnosis, beginning a journey of treatment and eventual survivorship.
- 2004–2023: Zafra ascends through the ranks of global procurement leadership, holding key roles at Agilent, HP, McKesson, and Twitter, eventually joining LiveRamp as Chief Procurement Officer.
- Early 2024: Following a rigorous vetting process by the CureSearch Governance Committee, Zafra is identified as a candidate who possesses both the professional acumen and personal passion required for board service.
- Summer 2024: Official announcement of Zafra’s appointment to the Board of Directors.
- Late 2024 (Projected): Zafra will complete the Ultimate Hike in Jackson, WY, marking his 20-year anniversary of survivorship and raising funds for the next generation of research.
Official Responses and Organizational Impact
The leadership at CureSearch has expressed significant optimism regarding Zafra’s ability to contribute to the organization’s long-term goals. Jared Brancazio, the Chair of the CureSearch Board of Directors, emphasized the dual nature of Zafra’s value to the team.
"Mark’s professional leadership and personal commitment to advancing cancer research make him an incredible addition to the CureSearch Board," Brancazio stated. "We’re honored to have him help guide our work and accelerate our impact."
Zafra himself viewed the appointment as both a professional honor and a personal responsibility. In his statement, he highlighted the importance of ensuring that the next generation of patients has access to better outcomes than those currently available. "As a survivor myself, I am a passionate advocate for advancing cancer research and am honored by the opportunity to contribute my skills and experience to a mission that matters deeply to me," Zafra shared.
The board’s expectation is that Zafra will provide oversight on the organization’s operational budget, help streamline the procurement of services for research initiatives, and leverage his professional network to expand CureSearch’s reach within the technology and corporate sectors.
Implications for the Future of Pediatric Oncology
The appointment of a Chief Procurement Officer to a medical research board signals a broader trend in the non-profit sector: the professionalization of philanthropy. As donors increasingly demand transparency and measurable results, non-profits are turning to executives who understand how to maximize "Return on Mission."
In the context of pediatric oncology, this means moving beyond general awareness and focusing on the mechanics of drug delivery. Zafra’s background in supply chains is particularly relevant as the world deals with ongoing shortages of critical chemotherapeutic agents. While CureSearch primarily focuses on research, the strategic mindset of a supply chain expert helps the organization understand the entire lifecycle of a treatment—from the laboratory bench to the pharmacy shelf.
Moreover, Zafra’s role at LiveRamp—a leader in data collaboration—suggests potential for CureSearch to further explore data-driven approaches to research. In modern oncology, the ability to aggregate and analyze vast amounts of genomic and clinical data is essential for developing personalized medicine. Having a board member who operates at the intersection of data and business strategy could prove pivotal as CureSearch continues to fund innovative digital health and precision medicine initiatives.
Conclusion and Outlook
As CureSearch for Children’s Cancer welcomes Mark Zafra, the organization reinforces its commitment to a multidisciplinary approach to solving the crisis of childhood cancer. By combining the lived experience of a survivor with the strategic discipline of a global procurement leader, CureSearch is well-positioned to continue its trajectory of high-impact advocacy and research funding.
The upcoming Ultimate Hike in Jackson, Wyoming, will serve as a public testament to Zafra’s dedication. As he navigates the trails of the Teton Range, he will be carrying the hopes of thousands of families who rely on CureSearch to find the next breakthrough. With a strengthened Board of Directors and a clear focus on operational efficiency, CureSearch remains a beacon of hope in the fight to ensure that every child diagnosed with cancer can look forward to a future as long and accomplished as Mark Zafra’s.
